Literature DB >> 10469246

Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine-transfected fibroblasts.

M L Grattone1, C L Villiers, M B Villiers, C Drouet, P N Marche.   

Abstract

CR1 and CR2 are expressed as associated proteins on the B-lymphocyte surface. To investigate their respective contributions to the internalization of C3 fragments, transfected murine fibroblasts expressing human CR1, CR2, or both CR1 and CR2 were produced. CR1- and CR1-CR2-expressing cells bound C3b and C3b-dimer whereas CR2- and CR1-CR2-expressing cells bound iC3b and C3de. In all cases, maximum binding was achieved at low ionic strength. CR1-CR2-positive cells internalized two- to threefold more C3b and 1.5-fold more iC3b than CR1- and CR2-single-positive cells, respectively. Internalization of the anti-CR1 antibody J3D3, or C3de was at the same level, in both double-transfected and single-transfected cells. Furthermore, the internalization of C3b dimer by CR1-CR2 cells was impaired in the presence of OKB7, an anti-CR2-blocking antibody, but it was not altered in CR1 cells. Taken together, these findings suggest that CR1 and CR2 collaborate to internalize C3b and iC3b proteins. We suggest that the induction of conformational changes of the ligands enhances their binding to both receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469246      PMCID: PMC2326894          DOI: 10.1046/j.1365-2567.1999.00839.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.

Authors:  Y Takebe; M Seiki; J Fujisawa; P Hoy; K Yokota; K Arai; M Yoshida; N Arai
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

Review 2.  Complement C3: a molecular mosaic of binding sites.

Authors:  Z Fishelson
Journal:  Mol Immunol       Date:  1991 Apr-May       Impact factor: 4.407

3.  Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells.

Authors:  J C Carel; B Frazier; T J Ley; V M Holers
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

4.  Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response.

Authors:  Y Fang; C Xu; Y X Fu; V M Holers; H Molina
Journal:  J Immunol       Date:  1998-06-01       Impact factor: 5.422

5.  Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.

Authors:  J C Carel; B L Myones; B Frazier; V M Holers
Journal:  J Biol Chem       Date:  1990-07-25       Impact factor: 5.157

6.  Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer.

Authors:  M A Arnaout; J Melamed; B F Tack; H R Colten
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

7.  Conformational changes accompanying proteolytic cleavage of human complement protein C3b by the regulatory enzyme factor I and its cofactor H. Spectroscopic and enzymological studies.

Authors:  D E Isenman
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

8.  Structural and functional studies of HLA-DR restricted antigen recognition by human helper T lymphocyte clones by using transfected murine cell lines.

Authors:  R I Lechler; V Bal; J B Rothbard; R N Germain; R Sekaly; E O Long; J Lamb
Journal:  J Immunol       Date:  1988-11-01       Impact factor: 5.422

9.  A simple alternative pathway for hemolytic assay of human complement component C3 using methylamine-treated plasma.

Authors:  T E Jessen; V Barkholt; K G Welinder
Journal:  J Immunol Methods       Date:  1983-05-27       Impact factor: 2.303

10.  Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.

Authors:  L B Klickstein; T J Bartow; V Miletic; L D Rabson; J A Smith; D T Fearon
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.